Antibiotice S.A. (ATB) Stock Price, Fundamentals & Analysis

What ATB does

Antibiotice S.A. (symbol ATB) is a Romanian company that produces and sells medicinal products in Romania and internationally. It operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, and is listed on the Bucharest Stock Exchange (BVB). The company manufactures generic prescription medicines, including anti-infectives and drugs for tuberculosis, as well as cardiovascular, digestive, gynecological, dermatological, and central nervous system preparations. It also offers generic non-prescription medicines, food supplements, cosmetics, medical devices, active pharmaceutical ingredients, biofertilizers, biocides, and veterinary medicines. Its products are available in various forms, including capsules, tablets, ointments, gels, creams, and injectable powders. Antibiotice S.A. exports its products to approximately 70 countries and has been headquartered in Iasi, Romania, since its founding in 1955.

Key numbers explained

• The current price is 1,86 RON, with a -1,48% change today.
• The trailing P/E ratio of 186 is calculated by dividing the current price by the trailing 12-month earnings per share of 0,01 RON; a high ratio can indicate high investor expectations or very low recent earnings.
• The dividend yield is 1,05%, meaning the annual dividend represents 1,05% of the current price.
• The ex-dividend date is 15 oct. 2026; to receive the dividend, you must own the stock before this date.
• The company pays out 170% of its earnings as dividends, which means the dividend exceeds the trailing 12-month net income per share.
• The beta of 0,21 suggests the stock's price tends to be less volatile than the overall market.
• The 52-week price range is 1,75 – 2,64 RON, with a -24,3% change over the last year.
• The debt-to-equity ratio of 38% indicates the company uses 38 units of debt for every 100 units of equity.

Recent news

Recent headlines include a General Shareholders' Meeting scheduled for 29/30.10.2026, a dividend proposal for 2025, another General Shareholders' Meeting on 30.09.2026, the publication of the semi-annual report for S1 2026, and a financial results teleconference for the first half of 2026.

What to watch

As a company in the Drug Manufacturers - Specialty & Generic industry, Antibiotice S.A. is influenced by regulatory changes in Romania and the EU, generic drug pricing pressures, and international trade dynamics. Its export orientation means currency fluctuations and geopolitical factors affecting the approximately 70 destination countries are relevant. Investors often compare it with peers like Ropharma SA (RPH), Biofarm S.A. (BIO), Med Life S.A. (M), and Farmaceutica Remedia SA (RMAH) to understand sector positioning. The company's relatively low beta of 0,21 may appeal to those seeking less volatility, while its high payout ratio of 170% warrants attention regarding dividend sustainability.